Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX101 subretinal gene therapy in prior control-group RPE65-IRD subjects
CTR20243797Phase 3Active
- Sponsor
- Lumsun Biotech
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 765IGF-MTX in Fundus dystrophy, sponsored by Lumsun Biotech. Started Nov 2024; status: active.
02
Drugs
765IGF-MTX
03
Conditions
Fundus dystrophy
Beyond the preview
Go deeper on CTR20243797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243797.